Hexarelin

What Hexarelin Does

Hexarelin (examorelin) is a synthetic hexapeptide growth hormone secretagogue that produces the strongest single-dose GH release of any GHRP currently available. Developed in the 1990s by Europeptides and investigated in clinical trials for GH deficiency and cardiovascular applications, Hexarelin occupies a unique pharmacological position: it delivers maximum acute GH output but at the cost of rapid receptor desensitization and the heaviest side effect burden of any GHRP.

Hexarelin’s second distinguishing feature is its cardioprotective activity. Unlike other GHRPs, Hexarelin binds CD36 (cluster of differentiation 36) receptors on cardiac myocytes, activating protective signaling pathways independent of growth hormone release. This dual mechanism — potent GH release plus direct cardiac protection — makes Hexarelin pharmacologically unique among GH secretagogues.

The mechanisms that matter:

• Strongest acute GH release — Hexarelin produces peak serum GH levels of 60–100+ ng/mL in a single dose, exceeding GHRP-2, GHRP-6, and Ipamorelin. The GH pulse occurs within 15–30 minutes and peaks at 30–60 minutes. For users who want the most powerful single-injection GH spike, Hexarelin is unmatched
• Rapid GHS-R1a desensitization — this is the trade-off. Hexarelin’s potent ghrelin receptor activation triggers more rapid receptor downregulation than other GHRPs. GH response begins declining within 2 weeks and is substantially blunted by 4 weeks. Other GHRPs (GHRP-2, Ipamorelin) maintain efficacy for 8–12 weeks. This desensitization is reversible with a 4-week washout
• CD36-mediated cardioprotection — Hexarelin binds CD36 scavenger receptors on cardiac cells, independent of GHS-R1a and independent of GH release. This activates PPARgamma signaling, reduces cardiac fibrosis, improves left ventricular ejection fraction, and protects against ischemic damage. This is a pharmacological effect unique to Hexarelin among GHRPs
• Significant cortisol and prolactin elevation — Hexarelin activates ACTH release (increasing cortisol) and prolactin secretion more aggressively than any other GHRP. At 200 mcg, cortisol elevation is clinically meaningful. Prolactin elevation is consistent and dose-dependent. This is the “dirtiest” GHRP profile
• Moderate appetite stimulation — less than GHRP-6 but more than Ipamorelin. The hunger effect is present but not overwhelming

Hexarelin vs Other GHRPs

Feature	Hexarelin	GHRP-2	GHRP-6	Ipamorelin
Peak GH release (single dose)	Highest (60–100+ ng/mL)	High (50–80 ng/mL)	Moderate–high (30–60 ng/mL)	Moderate (20–50 ng/mL)
Sustained GH release (over cycle)	Declines rapidly (2–4 weeks)	Maintained (8–12 weeks)	Maintained (8–12 weeks)	Maintained (8–12 weeks)
Cortisol elevation	Significant	Mild	Mild–moderate	None
Prolactin elevation	Significant	Mild	Mild	None
Appetite stimulation	Moderate	Moderate	Severe	Minimal
Desensitization speed	Fast (2–4 weeks)	Slow	Slow	Very slow
Cardioprotection	Yes (CD36-mediated)	No	No	No
Recommended cycle	4–8 weeks max	8–12 weeks	8–12 weeks	8–12 weeks
Best for	Short bursts, cardiac health	Maximum sustained GH	Bulking, appetite	Clean GH, anti-aging

When to choose Hexarelin: You want the absolute maximum GH pulse per injection — perhaps for a short, intense cycle before an event or competition. Or you are interested in the unique cardioprotective properties and plan to use a focused 4–6 week protocol. Hexarelin is not for long-term GH optimization because desensitization undermines sustained use.

When Hexarelin is the wrong choice: You want sustained GH elevation over 8–12 weeks (choose GHRP-2 or Ipamorelin). You want a clean side effect profile (choose Ipamorelin). You are cortisol-sensitive or concerned about prolactin (choose Ipamorelin). You want to avoid cycling complexity.

Dosing Protocol

Standard Protocol (With CJC-1295)

Parameter	Detail
Dose	100 mcg Hexarelin + 100 mcg CJC-1295 (no DAC) per injection
Frequency	2–3 times daily
Best timing	Morning (fasted), post-workout, pre-sleep
Cycle length	4–8 weeks on, 4 weeks off
Route	Subcutaneous injection

Keep cycles at 4–6 weeks for GH optimization. By week 4, desensitization is beginning. By week 8, the GH response is substantially blunted. Running Hexarelin for 12 weeks like you would Ipamorelin wastes product and provides diminishing returns.

Dose Tiers

Level	Hexarelin Dose	GH Release	Side Effect Profile
Cardioprotective focus	50–100 mcg, 1x daily	Moderate	Minimal cortisol/prolactin, CD36 activation present
Conservative GH	100 mcg, 2x daily	Strong	Moderate cortisol/prolactin
Standard GH	100 mcg, 3x daily	Very strong	Moderate–significant cortisol/prolactin
Aggressive GH	200 mcg, 2–3x daily	Near maximum (acute)	Significant cortisol/prolactin, accelerated desensitization

100 mcg is the recommended dose. The GH release from Hexarelin follows a saturation curve — 200 mcg produces only marginally more GH than 100 mcg but significantly more cortisol and prolactin. The 100 mcg dose provides the best benefit-to-side-effect ratio.

For cardioprotective purposes only: 50–100 mcg once daily for 4–6 weeks. The CD36 binding and downstream cardiac signaling do not require maximum GH release doses. This lower-dose approach may be appropriate for users interested in Hexarelin’s unique cardiac benefits without the full hormonal side effect burden.

Fasting Requirements

Same as all GH peptides:

• Fast 2+ hours before injection — insulin suppresses pituitary GH release. In a fed state, even Hexarelin’s potent stimulus is significantly blunted
• Wait 30–60 minutes after injection before eating — allow the GH pulse to complete
• Pre-sleep window is ideal — naturally fasted, and the GH pulse adds to the nocturnal surge
• Post-workout window is an exception — some users inject Hexarelin immediately post-workout and eat within 30 minutes. While this theoretically blunts GH release, the post-workout anabolic window may justify the trade-off. The pre-sleep dose should always be fully fasted

Reconstitution

For a 5 mg vial of Hexarelin — add 2.5 mL bacteriostatic water:

Dose	Volume to Draw
50 mcg	2.5 units on insulin syringe
100 mcg	5 units
200 mcg	10 units

Concentration: 2,000 mcg/mL. One 5 mg vial provides 50 doses at 100 mcg — roughly 17–25 days at 2–3 doses per day.

Combining with CJC-1295: Draw Hexarelin first, then draw CJC-1295 from its vial into the same syringe. Inject together immediately. Never pre-mix reconstituted peptides for storage.

Storage: Refrigerate at 2–8°C. Use within 28 days of reconstitution. Unreconstituted lyophilized powder can be frozen.

Cycling Strategy

Hexarelin cycling is more important than with any other GHRP because of the rapid desensitization:

• Standard: 4–6 weeks on, 4 weeks off
• Extended (with monitoring): 6–8 weeks on, 4–6 weeks off. Check GH response by week 6 — if morning injection no longer produces noticeable effects (improved sleep, vivid dreams, slight water retention), desensitization has set in
• Rotation strategy: Some advanced users rotate Hexarelin with other GHRPs — for example, 4 weeks Hexarelin for maximum GH burst, then switch to Ipamorelin for 8 weeks of sustained, clean GH release. This provides variety in GH stimulus without continuous Hexarelin desensitization
• Off-cycle bridge: MK-677 (oral) can maintain GH elevation during the Hexarelin off period since it does not desensitize the ghrelin receptor in the same manner. See MK-677 Protocol

What to Expect

Realistic Timeline

• Days 1–3: Significant GH pulse felt immediately — many users report flushing, tingling, and a “rush” sensation within minutes of injection. Sleep quality improves dramatically with pre-sleep dosing. Vivid dreams are common from night one. Some appetite increase and possible mild nausea at higher doses
• Week 1: The strongest GH response period. Sleep is deep and restorative. Recovery from training is noticeably enhanced. Water retention begins (indicates GH elevation). Cortisol effects may manifest as mild irritability or disrupted early-morning waking in sensitive individuals
• Weeks 2–3: GH effects remain strong but may begin plateauing. Body composition improvements become visible — improved muscle fullness, better skin quality. Recovery continues to be excellent. Prolactin elevation may become noticeable in sensitive males (slight breast tenderness in rare cases)
• Weeks 3–4: Desensitization begins in many users. The subjective “rush” from injection diminishes. Sleep benefits may plateau. This is the critical assessment point — if response is clearly declining, consider ending the cycle
• Weeks 4–8: Progressive desensitization. GH response continues declining toward baseline. The cardioprotective effects (if present) do not necessarily desensitize on the same timeline as GH release, as they are mediated through a different receptor (CD36). Most users end their cycle in this window

Who Benefits From Hexarelin

• Users wanting a short, intense GH protocol — Hexarelin’s 4–6 week optimal window suits users who prefer short bursts rather than long cycles
• Users interested in cardioprotection — the CD36-mediated cardiac effects are unique to Hexarelin
• Users rotating between GHRPs — Hexarelin fits well into a rotation strategy where different peptides provide different stimuli across the year
• Users with prior GHRP experience — Hexarelin is not a first GHRP. Start with Ipamorelin to understand GH peptide response before trying Hexarelin’s heavier profile

What the Research Says

Hexarelin has substantial clinical data, particularly for cardiac applications:

GH release potency (human data): Arvat et al. conducted head-to-head comparisons of GHRPs in healthy human subjects and demonstrated that Hexarelin produced the highest peak GH levels of any GHRP tested at equivalent doses. Peak serum GH exceeded 80 ng/mL in some subjects at 2 mcg/kg IV. The GH pulse onset was rapid (15 minutes) with peak at 30–60 minutes. Published in Journal of Clinical Endocrinology & Metabolism.

Desensitization kinetics: Locatelli et al. documented the time course of Hexarelin desensitization in human subjects. After 16 weeks of continuous Hexarelin administration, GH response was reduced to approximately 50% of the initial response. Shorter studies (4–8 weeks) showed the decline beginning at weeks 2–4. The desensitization was fully reversible with a 4-week washout period. Published in European Journal of Endocrinology.

Cardioprotective effects (CD36 pathway): Bhatt et al. demonstrated that Hexarelin binds CD36 scavenger receptors on cardiomyocytes, activating PPARgamma signaling and producing anti-fibrotic, anti-hypertrophic, and anti-ischemic effects. These effects were independent of GH release — the cardioprotection occurred even when GH release was blocked. This was a landmark finding that distinguished Hexarelin pharmacologically from all other GHRPs. Published in Circulation Research and Proceedings of the National Academy of Sciences (PNAS).

Cardiac function improvement: Bisi et al. studied Hexarelin in patients with ischemic heart disease and demonstrated improvement in left ventricular ejection fraction and reduction in cardiac fibrosis markers. The cardiac benefits were observed at doses that also produced GH release, though the mechanisms appeared to be independent. Published in European Heart Journal.

Cortisol and prolactin data: Rigorous endocrine profiling confirmed that Hexarelin at standard doses (1–2 mcg/kg) produces more substantial cortisol and prolactin increases than any other GHRP. ACTH-mediated cortisol peaks were typically 30–50% above baseline and returned to normal within 3–4 hours. Prolactin elevations were consistent and dose-dependent. Published in Neuroendocrinology.

Andrew Huberman has discussed the ghrelin receptor system and GH secretagogues broadly on the Huberman Lab podcast. While not covering Hexarelin specifically in depth, his explanations of GHS-R1a pharmacology and the distinction between GHRH-pathway and ghrelin-pathway GH release directly inform understanding of Hexarelin’s mechanism.

Derek (More Plates More Dates) has discussed Hexarelin’s position among GHRPs, noting the “strongest but shortest” characterization — maximum acute GH release but impractical for sustained use due to rapid desensitization. He generally recommends Ipamorelin + CJC-1295 as the standard protocol and positions Hexarelin as a niche choice for advanced users who understand the desensitization trade-off.

Safety

Common Side Effects

Side Effect	Frequency	Notes
Cortisol elevation	~40%	More significant than other GHRPs. Dose-dependent
Prolactin elevation	~35%	Consistent, dose-dependent. Monitor for gynecomastia signs
Water retention	~30%	Mild–moderate, indicates GH elevation
Appetite increase	~25%	Moderate — less than GHRP-6, more than Ipamorelin
Flushing/warmth	~20%	Transient, occurs within minutes of injection
Numbness/tingling	~15%	Carpal tunnel-like. Dose-dependent
Injection-site reaction	~10%	Minor redness, soreness
Headache	~10%	More common in first week
Vivid dreams	~25%	Usually considered a positive effect

Critical Warnings

Prolactin monitoring is essential. Hexarelin elevates prolactin more than any other GHRP. Sustained prolactin elevation can:

• Suppress testosterone production in males
• Cause gynecomastia (breast tissue growth) in sensitive individuals
• Produce galactorrhea (nipple discharge) in rare cases
• Cause menstrual irregularity in females

If running Hexarelin at 200 mcg or for cycles longer than 4 weeks, check prolactin levels. If elevated, reduce dose, shorten the cycle, or consider a dopamine agonist (cabergoline) — though adding another drug to manage side effects of a peptide should prompt reconsideration of whether Hexarelin is the right choice vs Ipamorelin.

Cortisol concerns at aggressive doses. Chronic cortisol elevation from high-dose Hexarelin use can impair recovery, increase visceral fat, disrupt sleep, and suppress immune function. These effects directly undermine the goals of GH peptide use. Stay at 100 mcg per dose.

Desensitization is real and predictable. Do not attempt to overcome desensitization by increasing the dose. Higher doses do not overcome receptor downregulation — they simply increase side effects while GH output remains blunted. When response declines, end the cycle and take 4 weeks off.

Fasting is mandatory. Same as all GH peptides — injecting in a fed state blunts GH release.

Not FDA-approved. Hexarelin (examorelin) was investigated in clinical trials but was never approved for therapeutic use. All use is experimental.

Banned by WADA. Hexarelin is specifically listed as a prohibited substance.

Cancer precaution. GH promotes cell growth. Do not use with active malignancies, recent cancer history, or significant cancer risk factors.

Do Not Use If

• Active cancer or tumor history
• Active acromegaly or pituitary tumors
• History of prolactin-sensitive conditions (prolactinoma, gynecomastia history)
• Active cardiovascular disease requiring medical management (discuss with cardiologist — the cardioprotective data is interesting but not a substitute for standard cardiac care)
• Uncontrolled diabetes
• Pregnant or breastfeeding
• Under 18 (active growth plates)
• Subject to WADA/USADA testing
• No prior experience with GH peptides (start with Ipamorelin)

What Comes Next

• Prefer sustained GH without desensitization? — Ipamorelin Protocol for clean, long-cycle GH optimization
• Pair with CJC-1295 in the Growth Hormone Stack for synergistic GH release
• Compare all GH peptides — Growth Hormone Peptides Compared
• Oral GH option — MK-677 Protocol for needle-free GH elevation with no desensitization
• Maximum GH without desensitization — GHRP-2 Protocol for the strongest sustained GHRP
• Use the Reconstitution Calculator for exact unit counts